America’s Stem Cell Mess
By Josephine Johnston,
The Scientist
| 10. 13. 2010
[Opinion]
It’s hard not to feel sorry for American embryonic stem cell (ESC) researchers. Over the dozen years since the cells were first derived, they’ve been expected to meet federal rules that change with each president, research guidelines from the National Academy of Sciences as interpreted by their institutions, and separate requirements from state and private funders. While the extremely restrictive policies of the Bush administration caused a number of alternative funders to step up to the plate, each comes with its own rules, restrictions, and reporting requirements. Labs with a mix of federal and private funding are required to account for the monies separately, leading to the somewhat absurd practice of color-coding lab instruments and workspace so that nothing paid for with federal money is used to do something federal policies prohibit.
The picture brightened last year when President Obama lifted his predecessor’s restrictions, allowing the National Institutes of Health (NIH) to release new guidelines for an expanded ESC research program. But this August, a judge issued a preliminary injunction putting that entire program on hold. NIH has appealed the...
Related Articles
By Carly Mallenbaum, Axios [cites Emily Galpern] | 03.29.2026
More Americans are turning to surrogacy to build their families, as the practice becomes more common and more publicly discussed.
Why it matters: As surrogacy becomes more visible and accessible, ethical, legal and cultural tensions become harder to ignore...
By Carly Mallenbaum, Axios [cites Surrogacy360] | 03.29.2026
Without a federal law, surrogacy in the U.S. is governed by a patchwork of state regulations/
Why it matters: Confusing, varied local rules can determine everything from whether agreements are legally binding to who is recognized as a parent at...
Cathy Tie seems to be good at starting businesses but not so dedicated to maintaining them. CGS, like many others, first heard of her thanks to Caiwei Chen and Antonio Regalado in MIT Technology Review, May 2025, as the partner (perhaps bride) of the notorious Chinese scientist He Jiankui, described in the headline as “China’s Frankenstein.” He prefers “Chinese Darwin.” She ran his Twitter account for a while, contributing such gems as:
Get in luddite, we’re going gene editing...
By Laura DeFrancesco, Nature Biotechnology | 03.17.2026
The first gene editors designed to fix genetic lesions in mutation-agnostic ways are poised to enter the clinic. Tessera Therapeutics and Alltrna, two Flagship Pioneering-funded companies, are gearing up to test novel genetic medicines in humans. Tessera received regulatory clearance...